Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
24.48 USD | -1.09% | -1.09% | -17.04% |
May. 10 | Morgan Stanley Adjusts Price Target on Mirum Pharmaceuticals to $53 From $57, Keeps Overweight Rating | MT |
May. 08 | Transcript : Mirum Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 08, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-17.04% | 1.17B | |
+34.61% | 50.85B | |
+0.52% | 42.82B | |
+49.62% | 42.03B | |
-4.96% | 29.55B | |
+10.68% | 26.11B | |
-21.56% | 19.13B | |
+8.65% | 13.05B | |
+26.96% | 12.16B | |
+24.12% | 12.08B |
- Stock Market
- Equities
- MIRM Stock
- News Mirum Pharmaceuticals, Inc.
- Mirum Pharmaceuticals Says US FDA Extends Supplemental NDA Review for Livmarli to March 13; Shares Fall After Hours